This open-label study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) as monotherapy or in combination with methotrexate or other non-biologic DMARDs in patients with severe rheumatoid arthritis and an inadequate response to an anti-tumour necrosis factor (anti-TNF) agent. Patients will receive RoActemra/Actemra 162 mg subcutaneously weekly for 52 weeks.

Read more: